Yes we offer both virtual and in-person appointments
The design incorporates an HIV-TAT cell-penetrating sequence, enabling efficient cellular uptake through energy-independent membrane translocation
These properties made it an attractive target for improving glycemic control while reducing the risk of hypoglycemia
Joshua Silva, MD, is a licensed physician and Medical Director of Potere Health MD
Mounjaro (tirzepatide) injection, for subcutaneous use, Food and Drug Administration (2026) FDA approves Lillys Mounjaro (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with Type 2 diabetes, Eli Lilly (2022) Mounjaro (tirzepatide) Injection: The first and only GIP and GLP-1 receptor agonist approved for Type 2 Diabetes, Eli Lilly Declaratory order: Resolution of shortages of tirzepatide injection products (Mounjaro and Zepbound), Food and Drug Administration (2024) FDAs concerns with unapproved GLP-1 drugs used for weight loss, Food and Drug Administration (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice